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Abstract
Introduction: Therapy with vitamin D3 analogs 
suppress the parathyroid hormone (PTH) secretion in 
chronic kidney disease (CKD) patients suffering from 
secondary hyperparathyroidism (sHPT). The concurrent 
administration of calcium-containing phosphate 
binders further increases the likelihood of developing 
hypercalcemia. Calcimimetics, such as cinacalcet, lower 
PTH level while limiting the risks of hyperphosphatemia 
and/or hypercalcemia. In adults, clinical experience with 
calcimimetics has shown significant reductions in PTH 
levels in cases with sHPT, but the clinical experience in 
children with CKD is limited. 
Case series: We report here the effect of short term 
use of cinacalcet on sHPT in two children on regular 
hemodialysis for CKD stage 5. Both children had very 
high PTH level which failed to be controlled with 
vitamin D3 and phosphate binders. We started cinacalcet 
therapy at a dose of 30 mg/day for both of them for 
duration of eight weeks. The first case was an 11 year-old 
male, his iPTH level decreased by 26% at four weeks 
after initiation of therapy and decreased by 39% at eight 
weeks. The second case was a 13 year-old female, her 
iPTH level decreased by 25% at four weeks after therapy 
and by 40% at eight weeks. There were no drug related 
side effects in both cases. Serum calcium and phosphorus 
levels remained stable in both patients.
Conclusion: Cinacalcet can be effectively used in the 
treatment of sHPT in children in the short term, with 
minimal changes in the serum levels of calcium and 
phosphorus. 
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Introduction
Therapy with an analog of 1,25 vitamin D3 and 
maintenance of low serum phosphorous levels, via 
dietary restriction of phosphorous intake and use of 
phosphate binders, suppress the PTH secretion by the 
parathyroid glands. This modality of therapy is used to 
treat secondary hyperparathyroidism (sHPT) in patients 
with chronic kidney disease (CKD) [1]. The concurrent 
administration of calcium-containing phosphate binding 
agents further increases the likelihood of developing 
hypercalcemia [2]. 
Accordingly, therapeutic strategies that lower 
parathyroid hormone (PTH) while limiting the risks 
of hyperphosphatemia and/or hypercalcemia, such as 
calcimimetics, are of considerable interest [3].
cinacalcet (Sensipar/Mimpara ®, Amgen, USA), a type 
II calcimimetic, allosterically increases the sensitivity of 
the calcium- sensing receptor, lowering the threshold for 
activation of parathyroid gland, and thereby decreasing 
secretion of parathyroid hormone (PTH) [4]. Studies 
have demonstrated its ability to lower PTH without 
significantly increasing serum calcium, phosphorus, and 
thus the calcium-phosphorus product [5].
We report here the effect of short term use of cinacalcet 
on sHPT in two children on regular hemodialysis for end 
stage kidney disease (ESKD). 
Cases Series
Both patients were on hemodialysis, using Fresenius 
2008K machines and hollow fiber polysulfone dialyzers 
(Fresenius, Bad Homburg, Germany), using standard 
dialysate solution. 
The routine dialysis prescription was as follows: three 
sessions per week, three hours per session and blood 
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flow rate of 300ml/min with target urea reduction ratio
> 65%. Both patients were on calcium carbonate 4000 mg/
day for phosphate binding and intravenous paricalcitol. 
Paricalcitol was initiated at 0.01 μg/kg according to the 
guidelines for iPTH > 800 pg/mL [6].
Case 1
A male aged 11 years was on regular hemodialysis for 
3.5 years, for ESRD due to sickle cell nephropathy. He 
had persistently high iPTH for the previous year though 
his serum calcium and phosphorus levels were within 
the accepted ranges. We initiated cinacalcet (Mimpara, 
Amgen, USA) at a dose of 30 mg/day and followed his 
serum calcium, phosphorus and iPTH at four weeks 
and eight weeks of therapy. The results showed iPTH 
reduction by 26% at four weeks and by 39.4% at eight 
weeks. Serum calcium was slightly decreased after four 
weeks of therapy, accordingly we increased the dose of 
calcium carbonate and decreased the dose of intravenous 
paricalcitol according to guidelines (for iPTH 500–800 
pg/mL give intravenous paricalcitol at 0.07 μg/kg) [6]. 
After this modification, serum calcium returned to near 
normal level. Serum phosphorus showed almost no 
change during this treatment (Table-1).
Case 2
A female aged 13.5 year on regular hemodialysis for 
ESRD due to chronic interstitial nephritis for the previous 
2.6 year. She also had high iPTH level that failed to 
be controlled with phosphate binders and intravenous 
paricalcitol. We initiated cinacalcet at a dose of 30 mg/
day and followed her serum calcium, phosphorus and 
iPTH levels at four and eight weeks of therapy. At four 
weeks, iPTH decreased by 25.3% and by 40.1% at eight 
weeks with almost no effect on both serum calcium and 
phosphorus levels (Table-2).
Discussion
Secondary hyperparathyroidism, a high-turnover bone 
disease (HTBD), is manifested by elevated parathyroid 
hormone (PTH) levels. Control of HTBD may be 
achieved by maintaining low serum phosphorous levels 
and administering vitamin D therapy, although some 
patients continue to exhibit high PTH levels [7]. Clinical 
studies have shown significant reduction in PTH levels, 
decrease in the size of the hyperplastic parathyroid 
gland, avoidance of vascular calcification with minimal 
changes in serum calcium and phosphate level with 
the use of calcimimetics. The clinical experience with 
the use of calcimimetic in children with chronic renal 
disease is extremely limited. This is primarily due to 
concerns regarding bone growth, because of localization 
of calcimimetics in chondrocytes [8] and the fact that 
activation of the calcium-sensing receptors in the growth 
plate induces longitudinal bone growth [9, 10]. The effect 
of cinacalcet on mineral homeostasis is less clear in 
pediatric CKD patients than adults; perhaps as a result of 
active skeletal growth and the consequent influx and efflux 
of these minerals from bones [11]. The data regarding its 
use in children is mainly dependent on clinical experience. 
The cases presented here were two children with sHPT 
for which conventional therapy with active vitamin D 
and phosphate binders failed to achieve acceptable iPTH 
level. Both achieved significant reduction in iPTH levels 
without adversely affecting calcium and phosphorus 
levels. Silverstein and co-workers have described similar 











iPTH (pg/ml) 796.8 835.6 901 666.3 546
Serum Calcium (mg/dl) 8.8 8.6 9.1 8.3 8.8
Serum phosphorus (mg/dl) 6.3 5.2 5.9 5.7 5.4











iPTH (pg/ml) 1067 1192 1230 918.3 733
Serum Calcium (mg/dl) 9.3 8.8 8.7 8.9 8.1
Serum phosphorus (mg/dl) 6.7 4.4 6.6 6.1 5.2
results in nine pediatric patients with a mean age of 
14.5 ± 1.0 years [7]. After three months of cinacalcet 
therapy, there was a 60 % decline in parathyroid hormone 
levels. Muscheites and colleagues have also shown that 
cinacalcet was efficacious in the treatment of poorly 
controlled and vitamin D unresponsive sHPT in seven 
patients on renal replacement therapy with a mean age of 
17 years (range 1.1-19). In these patients cinacalcet was 
given for four weeks at a dose of 0.25 mg/kg per day. 
There was a significant reduction in parathyroid hormone 
levels by approximately 74% [12]. Other studies used 
cinacalcet for longer duration, up to 3 years, as Platt and 
her colleges who reported six cases with at least 86% 
reduction in serum iPTH [10].
Conclusion
We conclude that the short-term use of cinacalcet can be 
effective on reducing sHPT with minimal changes in the 
serum levels of calcium and phosphorus. 
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flow rate of 300ml/min with target urea reduction ratio
> 65%. Both patients were on calcium carbonate 4000 mg/
day for phosphate binding and intravenous paricalcitol. 
Paricalcitol was initiated at 0.01 μg/kg according to the 
guidelines for iPTH > 800 pg/mL [6].
Case 1
A male aged 11 years was on regular hemodialysis for 
3.5 years, for ESRD due to sickle cell nephropathy. He 
had persistently high iPTH for the previous year though 
his serum calcium and phosphorus levels were within 
the accepted ranges. We initiated cinacalcet (Mimpara, 
Amgen, USA) at a dose of 30 mg/day and followed his 
serum calcium, phosphorus and iPTH at four weeks 
and eight weeks of therapy. The results showed iPTH 
reduction by 26% at four weeks and by 39.4% at eight 
weeks. Serum calcium was slightly decreased after four 
weeks of therapy, accordingly we increased the dose of 
calcium carbonate and decreased the dose of intravenous 
paricalcitol according to guidelines (for iPTH 500–800 
pg/mL give intravenous paricalcitol at 0.07 μg/kg) [6]. 
After this modification, serum calcium returned to near 
normal level. Serum phosphorus showed almost no 
change during this treatment (Table-1).
Case 2
A female aged 13.5 year on regular hemodialysis for 
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weeks, iPTH decreased by 25.3% and by 40.1% at eight 
weeks with almost no effect on both serum calcium and 
phosphorus levels (Table-2).
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Secondary hyperparathyroidism, a high-turnover bone 
disease (HTBD), is manifested by elevated parathyroid 
hormone (PTH) levels. Control of HTBD may be 
achieved by maintaining low serum phosphorous levels 
and administering vitamin D therapy, although some 
patients continue to exhibit high PTH levels [7]. Clinical 
studies have shown significant reduction in PTH levels, 
decrease in the size of the hyperplastic parathyroid 
gland, avoidance of vascular calcification with minimal 
changes in serum calcium and phosphate level with 
the use of calcimimetics. The clinical experience with 
the use of calcimimetic in children with chronic renal 
disease is extremely limited. This is primarily due to 
concerns regarding bone growth, because of localization 
of calcimimetics in chondrocytes [8] and the fact that 
activation of the calcium-sensing receptors in the growth 
plate induces longitudinal bone growth [9, 10]. The effect 
of cinacalcet on mineral homeostasis is less clear in 
pediatric CKD patients than adults; perhaps as a result of 
active skeletal growth and the consequent influx and efflux 
of these minerals from bones [11]. The data regarding its 
use in children is mainly dependent on clinical experience. 
The cases presented here were two children with sHPT 
for which conventional therapy with active vitamin D 
and phosphate binders failed to achieve acceptable iPTH 
level. Both achieved significant reduction in iPTH levels 
without adversely affecting calcium and phosphorus 
levels. Silverstein and co-workers have described similar 
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results in nine pediatric patients with a mean age of 
14.5 ± 1.0 years [7]. After three months of cinacalcet 
therapy, there was a 60 % decline in parathyroid hormone 
levels. Muscheites and colleagues have also shown that 
cinacalcet was efficacious in the treatment of poorly 
controlled and vitamin D unresponsive sHPT in seven 
patients on renal replacement therapy with a mean age of 
17 years (range 1.1-19). In these patients cinacalcet was 
given for four weeks at a dose of 0.25 mg/kg per day. 
There was a significant reduction in parathyroid hormone 
levels by approximately 74% [12]. Other studies used 
cinacalcet for longer duration, up to 3 years, as Platt and 
her colleges who reported six cases with at least 86% 
reduction in serum iPTH [10].
Conclusion
We conclude that the short-term use of cinacalcet can be 
effective on reducing sHPT with minimal changes in the 
serum levels of calcium and phosphorus. 
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